Recent Updates
Recently added Catalysts

Celiac Disease: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.6Buniverse median $1.20B
Allocated capital$788M$1.6B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank165/299crowding rank 176

Celiac Disease is uncontested. Forte Biosciences (FBRX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with FB102 in phase 2.

There is no public comparable to price it against. FBRX spreads its $1.6B market cap across 2 indications, so $788M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$788M of allocated capital sits in Celiac Disease, ranking it 165th of 299 indications by the money committed to it.

Companies developing drugs for Celiac Disease 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
FBRXForte BiosciencesFB102Phase 21$1.6BNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Celiac Disease counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Celiac Disease has one competitor and a median of $1.6B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Peanut Allergy1 company · $861M · median $861MUncontestedChronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontestedXerostomia1 company · $671M · median $1.3BUncontestedPsoriatic Arthritis1 company · $646M · median $1.3BUncontestedInflammatory Bowel Disease1 company · $609M · median $3.0BUncontestedLupus Nephritis5 companies · $589M · median $516MOrphan cornerSystemic Sclerosis4 companies · $582M · median $540MOrphan corner

Celiac Disease pipeline questions

Which biotech companies are developing drugs for Celiac Disease?

Forte Biosciences (FBRX, FB102, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Celiac Disease.

How advanced is the Celiac Disease pipeline?

Of the 1 clinical-stage programme in Celiac Disease, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Celiac Disease?

No. FBRX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Celiac Disease, which is why the indication is classified as uncontested.

When is the next Celiac Disease catalyst?

The next dated catalyst in Celiac Disease is FBRX on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map